AdaptHealth Corp. Q3 FY2026 earnings call

• Largest Capitated Contract Improvement: The West Coast operations associated with the largest capitated contract swung from a loss in Q2 to a positive contribution in Q3, achieving an approximate 10% margin (up from -4%). Management targets a 20% margin by Q4 2027, driven by reduced utilization (as pent-up demand cleared), lower capital spending, and a 12% reduction in dedicated headcount.
• Manufacturer Price Increase Mitigation: AdaptHealth reached a rebate agreement with a key manufacturer that terminated their contract and imposed price hikes. This resulted in $8 million of benefits in Q3, offsetting part of the estimated $30 million annual impact.
• Portfolio Refinement & Diabetes Sale: The sale of the diabetes health business to Cardinal Health is progressing, with a closing expected in early 2027. Approximately $60 million in corporate overhead will be released or absorbed post-close.
• Medline Bed Recall: AdaptHealth is actively managing the recall and replacement of Medline home care beds. While Medline beds represent a meaningful portion of the fleet, management expects Medline to cover replacement costs, though it remains a multi-quarter operational effort.
• Digital & Enterprise Sales Growth: The company’s app now has over 615,000 users. An AI-powered mask-fitting tool completed over 12,600 scans with a 94% order completion rate. Additionally, four new preferred provider agreements were signed with large health systems via the newly formed Enterprise Sales Team.

• Sleep Health: Net revenue of $393.9 million, up 11% year-over-year.
• Respiratory Health: Net revenue of $190.8 million, up 7.8% year-over-year.
• Wellness at Home: Net revenue of $161.0 million, up 14.5% year-over-year.
• Total Capitated Revenue: $110.3 million, representing approximately 15% of continuing operations net revenue.

• Full-Year 2026 Net Revenue: Raised to $2.88 billion–$2.90 billion (midpoint up ~$20 million) due to Q3 outperformance and slower-than-expected decline in PCS product marketing.
• Full-Year 2026 Adjusted EBITDA: Raised to $510 million–$525 million (midpoint up $12 million) based on Q3 results and September run-rate margins on the capitated contract.
• Full-Year 2026 Free Cash Flow: Lowered to $55 million–$80 million (prior range was higher). The downward revision reflects working capital decisions to prioritize early payment discounts over cash accumulation.
• Fourth Quarter 2026 Estimates: Implied net revenue of $715 million–$735 million and adjusted EBITDA of $130 million–$145 million.
• Assumptions: Guidance assumes no unilateral changes to the largest capitated contract pricing and no further improvement in manufacturer pricing beyond current arrangements.

• Capitated Contract Execution Risk: The largest capitated contract faced significant headwinds due to higher-than-expected utilization and cost-to-serve issues. While stabilizing, failure to achieve the targeted 20% margin could impact profitability.
• Manufacturer Pricing Volatility: A major manufacturer imposed immediate price increases and terminated a contract, impacting economics. Although rebates mitigate this, future negotiations carry uncertainty regarding final pricing structures.
• Medline Field Action Costs: The recall and replacement of Medline beds involve operational complexity and potential financial exposure if Medline does not fully cover costs or if unforeseen liabilities arise.
• Goodwill Impairment: The quarter included a $194.8 million non-cash goodwill impairment charge triggered by declines in equity market capitalization, reflecting valuation risks.
• Working Capital Management: Decisions to accelerate vendor payments for discounts have reduced free cash flow, requiring careful balance sheet management as the company approaches debt reduction targets.

Q: How should investors size the recent capitated and preferred provider agreements, and what is the growth contribution expected through 2027? / A: Management highlighted two new regional capitated deals covering 72,000 lives, generating $7-8 million annually. These are stable, exclusive arrangements similar to existing successful contracts like Humana. For preferred provider agreements, the new Enterprise Sales Team secured four major health system deals. These provide 'chunky' volume and strategic access to discharge planning, though specific 2027 revenue numbers were not provided, emphasizing the value of streamlined referrals and liaison support.